Revolutionary Platform for Concurrent Administration of Two Cancer-Fighting Drugs
A groundbreaking technology developed by researchers from Israel, Italy, Portugal, and the Netherlands enables the simultaneous delivery of two different drugs to the tumor-affected areas in a patient’s body. The University of Tel Aviv announced this innovation in a press release, reported by Xinhua and Agerpres.
Conventional cancer treatments often involve combining drugs to enhance therapeutic effectiveness. However, differences in drug properties, such as degradation rates, circulation times, and tumor penetration levels, can hinder their co-localization in tumor areas, limiting their combined efficacy.
To maximize effectiveness and minimize toxicity, researchers have created a novel platform that transports two drugs simultaneously and selectively to the tumor site without impacting healthy organs. This method, detailed in the journal Science Advances, uses biodegradable polymeric nanoparticles to encapsulate pairs of drugs designed for specific cancer types, including skin and breast cancer.
The platform was tested using two drug pairs for skin and breast cancer on 3D cancer cell models and animal models. Results showed that the nanoparticles accumulated selectively in primary tumors without affecting healthy tissues and successfully penetrated the blood-brain barrier to reach brain metastases.
Simultaneous administration of both drugs proved significantly more efficient than separate administration, reducing tumor size and prolonging the lifespan of laboratory mice. The researchers concluded that this versatile platform can transport various drug pairs that reinforce each other’s effects, improving treatments for primary tumors and metastases expressing the P-selectin protein.
Keywords: Cancer treatment, drug delivery, targeted therapy, medical innovation, cancer research.
